Alogliptin Benzoate and Emicizumab

• Generic Name: alogliptin
• Dosage Forms: n.a.
• Other Brand Names: Nesina

Used as monotherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.

Used in combination with pioglitazone (given separately or as the fixed combination) as initial therapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both alogliptin and pioglitazone is appropriate.

Used in combination with metformin (given separately or as the fixed combination) as initialtherapy as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus when treatment with both alogliptin and metformin is appropriate.

Used in combination with other oral antidiabetic agents (e.g., metformin, a sulfonylurea, a thiazolidinedione [peroxisome proliferator-activated receptor-γ agonist]) or insulin as an adjunct to diet and exercise in patients with type 2 diabetes mellitus who have not achieved adequate glycemic control.

American Association of Clinical Endocrinologists/American College of Endocrinology (AACE/ACE) suggests a DPP-4 inhibitor as one of several alternatives for initial monotherapy in patients with metformin contraindications (e.g., renal disease, hepatic disease, GI intolerance, risk of lactic acidosis). DPP-4 inhibitors also recommended as part of combination therapy, particularly when both postprandial and fasting plasma glucose concentrations are elevated.

Not indicated for use in patients with type 1 diabetes mellitus or diabetic ketoacidosis.

• Generic Name: emicizumab
• Dosage Forms: n.a.
• Other Brand Names: Hemlibra, Hemlibra 105 mg/07 mL, Hemlibra 60 mg/04 mL

Emicizumab functions in place of a natural blood-clotting factor that is missing in people with hemophilia A. Emicizumab works as a "bridge" between other clotting factors to replace missing factor VIII.

Emicizumab is for adults and children with hemophilia A, with or without factor VIII inhibitors. Emicizumab is used to help prevent bleeding episodes or make them occur less often.

Emicizumab will not stop a bleeding episode that has already begun.

Emicizumab may also be used for purposes not listed in this medication guide.